SCHEMBL4497619

SCHEMBL4497619

CCN(CC)C(=O)c1ccc(N(Cc2ccccc2)C2CCN(C(C)C)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 17/20 0.54
OPRM1 P35372 14/20 0.54
OPRK1 P41145 12/20 0.54
CCR5 P51681 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4492889 0.88 OPRD1 (0.61) OPRD1OPRM1OPRK1
SCHEMBL4497092 0.85 OPRD1 (0.60) OPRD1OPRM1OPRK1
SCHEMBL4495917 0.82 OPRD1 (0.74) OPRD1OPRM1OPRK1
SCHEMBL4491008 0.82 OPRD1 (0.57) OPRD1OPRM1OPRK1
SCHEMBL4487446 0.81 OPRD1 (0.58) OPRD1OPRM1OPRK1
SCHEMBL3539247 0.78 CCR5 (0.58) OPRM1CCR5
Trifluoroacetic Acid SCHEMBL7462355 0.77 OPRM1 (0.51) OPRD1OPRM1
Trifluoroacetic Acid SCHEMBL7462360 0.77 OPRM1 (0.51) OPRD1OPRM1
SCHEMBL4496799 0.76 OPRM1 (0.64) OPRD1OPRM1OPRK1
SCHEMBL4499128 0.75 OPRD1 (0.56) OPRD1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576105-B2 Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives JANSSEN PHARMACEUTICA, NV (BE) 2009-08-18 US disclosed
US-20060106066-A1 Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives BAXTER ELLEN W 2006-05-18 US disclosed
WO-2004035541-A1 BENZYL SUBSTITUTED (PIPERIDIN-4-YL) AMINOBENZAMIDO DERIVATIVES AS DELTA-OPIOD RECEPTOR MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2004-04-29 WO disclosed
US-20040082612-A1 Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives JANSSEN PHARMACEUTICALS N.V. (BE) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106066-A1 Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives OPRD1, OPRK1, OPRM1 OPRD1 1/4885OPRM1 3/4885OPRK1 2/4885
US-20040082612-A1 Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives OPRD1, OPRK1, OPRM1 OPRD1 1/4885OPRM1 3/4885OPRK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.